Amylin, amyloid and age-related disease

Drugs and Aging

Volumn 9, Issue 3, 1996, Pages 202-212

  Cooper, Garth J S ^a   Tse, Cynthia A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; CALCITONIN GENE RELATED PEPTIDE; CELL SURFACE RECEPTOR; INSULIN; NEUROPEPTIDE; VASODILATOR AGENT;

AGING; CARBOHYDRATE METABOLISM; ESSENTIAL HYPERTENSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STRUCTURE; RECEPTOR BINDING; REVIEW; SKELETAL MUSCLE;

EID: 0029748283     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199609030-00006     Document Type: Review

References (133)

1. Cooper GJS, Willis AC, Clark A, et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-32
2. Westermark P, Wernstedt C, Wilander E, et al. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 1987; 84: 3881-5
3. Cooper GJS, Day AJ, Willis AC, et al. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochim Biophys Acta 1989; 1014: 247-58
4. Johnson KH, O'Brien TD, Betsholtz C, et al. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med 1989; 321: 513-8
5. Kanatsuka A, Makino H, Ohsawa H, et al. Secretion of islet amyloid polypeptide in response to glucose. FEBS Lett 1989; 259: 199-201
6. Ogawa A, Harris V, McCorkle SK, et al. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990; 85: 973-6
7. Kahn SE, D'Alessio DA, Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 1990; 39: 634-8
8. Moore CX, Cooper GJS. Co-secretion of amylin and insulin from cultured islet β-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 1991; 179: 1-9
9. Westermark P, Wilander E. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 1978; 15: 417-21
10. Cooper GJS, Leighton B, Willis AC, et al. The amylin superfamily: a novel grouping of biologically active polypeptides related to the insulin A-chain. Prog Growth Factor Res 1989; 1: 99-105
11. Ishida-Yamamoto A, Tohyama M. Calcitonin gene-related peptide in the nervous tissue. Prog Neurobiol 1989; 33: 335-86
12. Brain SD, Williams TJ, Tippins JR, et al. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 54-6
13. Girgis SI, MacDonald DWR, Stevenson JC, et al. Calcitonin gene-related peptide: potent vasodilator and major product of the Calcitonin gene. Lancet 1985; II: 14-6
14. O'Halloran DJ, Bloom SR. Calcitonin gene related peptide: a major neuropeptide and the most powerful vasodilator known [editorial]. BMJ 1991; 302: 739-40
15. Cooper GJS. Amylin compared with Calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 1994; 15: 163-201
16. Cooper GJS, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85: 7763-6
17. Leighton B, Cooper GJS. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988; 335: 632-5
18. Young DA, Deems RO, Deacon RW, et al. Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 1990; 259: E457-61
19. Molina JM, Cooper GJS, Leighton B, et al. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 1990; 39: 260-5
20. Koopmans SJ, van Mansfeld ADM, Jansz HS, et al. Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia 1991; 34: 218-24
21. Frontoni S, Choi SB, Banduch D, et al. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991; 40: 568-73
22. Leighton B, Foot E. The effects of amylin on carbohydrate metabolism in skeletal muscle in vitro and in vivo. Biochem J 1990; 269: 19-23
23. Young AA, Mott DM, Stone K, et al. Amylin activates glycogen phosphorylase in the isolated soleus muscle of the rat. FEBS Lett 1991; 281: 149-51
24. Deems RO, Deacon RW, Young DA. Amylin activates glycogen phosphorylase and inactivates glycogen synthase via a cAMP-independent mechanism. Biochem Biophys Res Commun 1991; 174: 716-20
25. Gómez-Foix AM, Rodriguez-Gil JE, Guinovart JJ. Anti-insulin effects of amylin and calcitonin gene-related peptide on hepatic glycogen metabolism. Biochem J 1991; 276: 607-10
26. 8-37h-CGRP antagonizes actions of amylin on carbohydrate metabolism in vitro and in vim. FEBS Lett 1991; 291: 195-8
27. Sowa R, Sanke T, Hirayama J, et al. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 1990; 33: 118-20
28. Young AA, Gedulin B, Wolfe-Lopez D, et al. Interaction of amylin and insulin in the isolated soleus muscle of the rat: concentration-response relations for co-secreted non-competitive antagonists. Am J Physiol 1992; 263: E274-81
29. Leighton B, Cooper GJS. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 1990; 15: 295-9
30. Bretherton-Watt D, Ghatei MA, Bloom SR, et al. Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes. Diabetologia 1989; 32: 881-3
31. Gill AM, Yen TT. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice. Life Sci 1991; 48: 703-10
32. Jamal H, Bretherton-Watt D, Suda K, et al. Islet amyloid polypeptide-like immunoreactivity (amylin) in rats treated with dexamethasone and streptozotocin. J Endocrinol 1990; 126: 425-9
33. Huang H-JS, Young AA, Koda JE, et al. Hyperamylinemia, hyperinsulinemia, and insulin resistance in genetically obese LA/N-cp rats. Hypertension 1992; 19 Suppl. I: 1101-9
34. Gedulin B, Cooper GJS, Young AA. Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res Commun 1991; 180: 782-9
35. Cooper GJS. Amylin and insulin co-replacement therapy for insulin-dependent (type I) diabetes mellitus. Med Hypoth 1991; 36: 284-8
36. Lukinius A, Wilander E, Westermark GT, et al. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989; 32: 240-4
37. Clark A, Edwards CA, Ostle LR, et al. Localization of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type-2 diabetic subjects. Cell Tissue Res 1989; 257: 179-85
38. Kassir AA, Upadhyay AK, Lim TJ, et al. Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 1991; 40: 998-1004
39. Butler PC, Chou J, Carter WB, et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990; 39: 752-6
40. Steiner DF, Ohagi S, Nagamatsu S, et al. Is islet amyloid polypeptide a significant factor in pathogenesis or pathophysiology of diabetes? Diabetes 1991; 40: 305-9
41. Tedstone AE, Nezzer T, Hughes SJ, et al. The effect of islet amyloid polypeptide (amylin) and calcitonin gene-related peptide on glucose removal in the anaesthetized rat and on insulin secretion from rat pancreatic islets in vitro. Biosci Rep 1990; 10: 339-45
42. Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 1990; 33: 115-7
43. Datta HK, Zaidi M, Wimalawansa SJ, et al. In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem Biophys Res Commun 1989; 162: 876-81
44. Bell GI. Molecular defects in diabetes mellitus. Diabetes 1991; 40: 413-22
45. Westermark P, Johnson KH, O'Brien TD, et al. Islet amyloid polypeptide - a novel controversy in diabetes research. Diabetologia 1992; 35: 297-303
46. Ammon HP, Reiber C, Verspohl EJ. Indirect evidence for short-loop negative feedback of insulin secretion in the rat. J Endocrinol 1991; 128: 27-34
47. Ohsawa H, Kanatsuka A, Yamaguchi T, et al. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 1989; 160: 961-7
48. Nagamatsu S, Carroll RJ, Grodsky GM, et al. Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets. Diabetes 1990; 39: 871-4
49. Nagamatsu S, Nishi M, Steiner DF. Effects of islet amyloid polypeptide (IAPP) on insulin biosynthesis or secretion in rat islets and mouse βTC3 cells: biosynthesis of IAPP in mouse βTC3 cells. Diab Res Clin Pract 1992; 15: 49-55
50. Broderick CL, Brooke GS, DiMarchi RD, et al. Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. Biochem Biophys Res Commun 1991; 177: 932-8
51. Fehmann H-C, Weber V, Göke R, et al. Islet amyloid polypeptide (IAPP; amylin) influences the endocrine but not the exocrine rat pancreas. Biochem Biophys Res Commun 1990; 167: 1102-8
52. Silvestre RA, Peiró E, Dégano P, et al. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 1990; 31: 23-31
53. Kogire M, Ishizuka J, Thompson JC, et al. Inhibitory action of islet amyloid polypeptide and calcitonin gene-related peptide on release of insulin from the isolated perfused rat pancreas. Pancreas 1991; 6: 459-63
54. Peirö E, Dégano P, Silvestre RA, et al. Inhibition of insulin release by amylin is not mediated by changes in somatostatin output. Life Sci 1991; 49: 761-5
55. Fürnsinn C, Leuvenink H, Roden M, et al. Inhibition of glucose induced secretion by amylin in rats in vitro [abstract]. Diabetologia 1992; 35 Suppl. 1: A29
56. Wang ZL, Bennet WM, Ghatei MA, et al. Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 1993; 42: 330-5
57. Dégano P, Silvestre RA, Salas M, et al. Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner: study in the perfused rat pancreas. Regul Pept 1993; 43: 91-6
58. Chuang LM, Wu HP, Jou TS, et al. Inhibitory effect of islet amyloid polypeptide on glucose-induced proinsulin biosynthesis in rat insulinoma cells. Pancreas 1992; 7: 472-6
59. 8-37hCGRP, an amylin receptor antagonist, enhances the insulin response and perturbs the glucose response to infused arginine in anaesthetized rats. Mol Cell Endocrinol 1992; 84: R1-5
60. Silvestre RA, Salas M, Degano P, et al. Reversal of the inhibitory effects of calcitonin gene-related peptide (CGRP) and amylin on insulin secretion by the 8-37 fragment of human CGRP. Biochem Pharmacol 1993; 45: 2343-7
61. Wagoner PK, Chen C, Worley JF, et al. Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling. Proc Natl Acad Sci USA 1993; 90: 9145-9
62. Barakat A, Marie J-C, Rosselin G. Direct interaction of islet amyloid polypeplide (IAPP) with calcitonin gene-related peptide (CGRP) receptor present in β cell membrane [abstract]. Diabetologia 1990; 33: A112
63. Pettersson M, Ahren B, Bottcher G, et al. Calcitonin gene-related peptide: occurrence in pancreatic islets in the mouse and the rat and inhibition of insulin secretion in the mouse. Endocrinology 1986; 119: 865-9
64. Ahren B, Pettersson M. Calcitonin gene-related peptide (CGRP) and amylin and the endocrine pancreas. Int J Pancreatol 1990; 6: 1-15
65. Barakat A, Marie J-C, Rosselin G. Le récepteur du peptide apparente au gene de la calcitonine (CGRP) est présent sur les membranes des insulinomes. C R Acad Sci III 1990; 310: 189-94
66. Lewis CE, Clark A, Ashcroft SJ, et al. Calcitonin gene-related peptide and somatostatin inhibit insulin release from individual rat B cells. Mol Cell Endocrinol 1988; 57: 41-9
67. Young AA, Wang MW, Cooper GJS. Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett 1991; 291: 101-4
68. Young AA, Cooper GJS, Carlo P, et al. Response to intravenous injections of amylin and glucagon in fasted, fed, and hypoglycemic rats. Am J Physiol 1993; 264: E943-50
69. Weischselbaum A, Stangl E. Zur Kenntniss der feineren Veränderungen des Pankreas bei Diabetes mellitus. Wien Klin Wochenschr 1901; 14: 968-72
70. Opie EL. On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med 1900-01; 5: 397-428
71. Opie EL. The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islands of Langerhans. J Exp Med 1900-01; 5: 527-40
72. Bell ET. Hyalinization of the islets of Langerhans in non-diabetic individuals. Am J Pathol 1959; 35: 801-5
73. Ahronheim JH. The nature of the hyaline material in the pancreatic islands in diabetes mellitus. Am J Pathol 1943; 19: 873-82
74. Ehrlich JC, Ratner IM. Amyloidosis of the islets of Langerhans. Am J Pathol 1961; 38: 49-59
75. Clark A, Cooper GJS, Lewis CE, et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 1987; II: 231-4
76. Porte Jr D, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet beta-cell dysfunction? Diabetes 1989; 38: 1333-6
77. Fox N, Schrementi J, Nishi M, et al. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett 1993; 323: 40-4
78. Hoppener JW, Oosterwijk C, Verbeek SJ, et al. IAPP/amylin transgenic mice as an in vivo model system for type-2 diabetes mellitus? Biochem Soc Trans 1993; 21: 28S
79. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 1994; 368: 756-60
80. Himsworth H. Diabetes mellitus: a differentiation into insulin-sensitive and insulin-insensitive types. Lancet 1936; 1: 127-30
81. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 1988; 37: 667-87
82. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
83. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellilus in the rhesus monkey. Diabetologia 1986; 29: 713-9
84. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217-25
85. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337-43
86. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 702-6
87. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7
88. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74
89. Enoki S, Mitsukawa T, Takemura J, et al. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 97-102
90. Hanabusa T, Kubo K, Oki C, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1992; 15: 89-96
91. Kautzky-Willer A, Thomaseth K, Pacini G, et al. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 1994; 37: 188-94
92. Brands MW, Hall JE. Insulin resistance, hyperinsulinemia, and obesity-associated hypertension [editorial]. J Am Soc Nephrol 1992; 3: 1064-77
93. Hall JE, Brands MW, Mizelle HL, et al. Chronic intrarenal hyperinsulinemia does not cause hypertension. Am J Physiol 1991; 260: F663-9
94. Briffeuil P, Huynh-Thu T, Kolanowski J. Reappraisal of the role of insulin on sodium handling by the kidney: effect of intrarenal insulin infusion in the dog. Eur J Clin Invest 1992; 22: 523-8
95. Hall JE, Brands MW, Hildebrandt DA, et al. Obesity-associated hypertension: hyperinsulinemia and renal mechanisms. Hypertension 1992; 19(1 Suppl.): 145-55
96. Hall JE, Coleman TG, Mizelle HL, et al. Chronic hyperinsulinemia and blood pressure regulation. Am J Physiol 1990; 258: F722-31
97. Anderson EA, Balon TW, Hoffman RP, et al. Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans. Hypertension 1992; 19: 621-7
98. O'Brien T, Young Jr WF, Palumbo PJ, et al. Hypertension and dyslipidemia in patients with insulinoma. Mayo Clin Proc 1993; 68: 141-6
99. Sawicki PT, Baba T, Berger M, et al. Normal blood pressure in patients with insulinoma despite hyperinsulinemia and insulin resistance. J Am Soc Nephrol 1992; 3 Suppl. 4: S64-8
100. Sawicki PT, Heinemann L, Starke A, et al. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 1992; 35: 649-52
101. Zimmermann S, Phillips RA, Dunaif A, et al. Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. J Clin Endocrinol Metab 1992; 75: 508-13
102. Nosadini R, Fioretto P, Trevisan R, et al. Insulin-dependent diabetes mellitus and hypertension. Diabetes Care 1991; 14: 210-9
103. Jarrett RJ. In defence of insulin: a critique of syndrome X. Lancet 1992; 340: 469-71
104. McAreavey D, Robertson JI. Angiotensin converting enzyme inhibitors and moderate hypertension. Drugs 1990; 40: 326-45
105. Predel HG, Dusing R, Backer A, et al. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. Am J Cardiol 1987; 59: 143D-8D
106. Donnelly R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 1992; 20 Suppl. 11: S38-44
107. Gotz R, Heidbreder E, Heidland A. Angiotensin-converting enzyme inhibition in renal and hypertensive disorders. Clin Physiol Biochem 1990; 8 Suppl. 1: 25-32
108. Kramer HJ, Predel HG, Meyer-Lehnert H. Angiotensin-converting enzyme inhibition in patients with essential hypertension. Clin Physiol Biochem 1990; 8 Suppl. 1: 16-24
109. Beaumont K, Kenney MA, Young AA, et al. High affinity amylin binding sites in rat brain. Mol Pharmacol 1993; 44: 493-7
110. 12 muscle cell line through a cholera-toxin-sensitive mechanism. Biochim Biophys Acta 1992; 1136: 219-22
111. D'Santos CS, Gatti A, Poyner DR, et al. Stimulation of adenylate cyclase by amylin in CHO-KI cells. Mol Pharmacol 1992; 41: 894-9
112. Nieuwenhuis MG, van Hulst KL, Hackeng WHL, et al. Islet amyloid polypeptide plasma concentrations in patients with insulinoma [abstract]. Diabetologia 1992; 35 Suppl. 1: A119
113. Stridsberg M, Wilander E, Oberg K, et al. Islet amyloid poly-peptide-producing pancreatic islet cell tumor: a clinical and biochemical characterization. Scand J Gastroenterol 1992; 27: 381-7
114. Stridsberg M, Berne C, Sandler S, et al. Inhibition of insulin secretion, but normal peripheral insulin sensitivity, in a patient with a malignant endocrine pancreatic tumour producing high amounts of an islet amyloid polypeptide-like molecule. Diabetologia 1993; 36: 843-9
115. Furnsinn C, Nowotny P, Roden M, et al. Insulin resistance caused by amylin in conscious rats is independent of induced hypocalcaemia and fades during long-term exposure. Acta Endocrinol 1993; 129: 360-5
116. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4: 2881-9
117. Dublineau I, Pradelles P, de Rouffignac C, et al. Differential short-term desensitization to vasopressin, isoproterenol, glucagon, parathyroid hormone and calcitonin in the thick ascending limb of rat kidney. Pflugers Arch 1992; 420: 16-22
118. Bawab W, Chastre E, Gespach C. Functional and structural characterization of the secretin receptors in rat gastric glands: desensitization and glycoprotein nature. Biosci Rep 1991; 11: 33-42
119. Dublineau B, Pradelles P, de Rouffignac C, et al. In vitro desensitization of isolated nephron segments to vasopressin. Proc Natl Acad Sci USA 1990; 87: 7583-7
120. Wilding JPH, Khandan-Nia N, Bennet WM, et al. Lack of acute effect of amylin (islet amyloid polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 1994; 37: 166-9
121. Bretherton-Watt D, Gilbey SG, Ghatei MA, et al. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 1992; 74: 1032-5
122. Roberts AN, Leighton B, Todd JA, et al. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc Natl Acad Sci USA 1989; 86: 9662-6
123. Cooper ME, McNay PG, Phillips PA, et al. Amylin stimulates plasma renin concentrations in humans. Hypertension 1995; 26: 460-4
124. Brain SD, Wimalawansa S, MacIntyre I, et al. The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit. Am J Pathol 1990; 136: 487-90
125. Young AA, Rink TJ. Wang MW. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat. Life Sci 1993; 52: 1717-26
126. Gardiner SM, Compton AM, Kemp PA, et al. Antagonistic effect of human alpha-calcitonin gene-related peptide (8-37) on regional hemodynamic actions of rat islet amyloid polypeptide in conscious Long-Evans rats. Diabetes 1991; 40: 948-51
127. 14C-glycogen accumulation. Biochem Biophys Res Commun 1992; 181: 116-20
128. Huang H-JS, Cooper GJS, Young AA, et al. Deficiency of amylin expression in the pancreas of autoimmune BB/Wor diabetic rats [abstract]. J Cell Biochem 1991; Suppl. 15B: 67
129. Bretherton-Watt D, Ghatei MA, Legon S, et al. Depletion of islet amyloid polypeptide in the spontaneously diabetic (BB) Wistar rat. J Mol Endocrinol 1991; 6: 3-7
130. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its cosecretion with insulin in humans. Diabetologia 1991; 34: 52-4
131. Sanke T, Hanabusa T, Nakano Y, et al. Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1991; 34: 129-32
132. Young AA, Crocker LB, Wolfe-Lopez D, et al. Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett 1991; 287: 203-5
133. Kolterman OG, Gottlieb A, Moyses C, et al. Reduction of post-prandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 1995; 18: 1179-82